Cargando…
Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis
BACKGROUND: Few data are available so far on the antibody-mediated immune response to anti-SARS-Cov2 vaccination in people with multiple sclerosis (pwMS) treated with disease-modifying treatments (DMTs), therefore this issue was explored in a real-life cohort of pwMS. MATERIALS AND METHODS: Retrospe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891428/ https://www.ncbi.nlm.nih.gov/pubmed/35239006 http://dx.doi.org/10.1007/s00415-022-11003-3 |
_version_ | 1784661871768371200 |
---|---|
author | Mariottini, Alice Bertozzi, Andrea Marchi, Leonardo Di Cristinzi, Maria Mechi, Claudia Barilaro, Alessandro Massacesi, Luca Repice, Anna Maria |
author_facet | Mariottini, Alice Bertozzi, Andrea Marchi, Leonardo Di Cristinzi, Maria Mechi, Claudia Barilaro, Alessandro Massacesi, Luca Repice, Anna Maria |
author_sort | Mariottini, Alice |
collection | PubMed |
description | BACKGROUND: Few data are available so far on the antibody-mediated immune response to anti-SARS-Cov2 vaccination in people with multiple sclerosis (pwMS) treated with disease-modifying treatments (DMTs), therefore this issue was explored in a real-life cohort of pwMS. MATERIALS AND METHODS: Retrospective monocentric study on anti-spike protein antibody response in pwMS who had received vaccination for Sars-Cov2. Adverse events following vaccination were also recorded. RESULTS: One hundred and twenty pwMS were included: 83 females (69%); median age at vaccination 42 years (range 21–73); 112/120 patients (93%) were receiving DMTs at vaccination. Anti-spike protein IgG antibodies were detectable in 102/120 (85%) cases overall, being the proportion lower in pwMS receiving anti-CD20 antibodies (14/31, 45%) compared to non-depletive treatments (77/78, 99%), p < 0.0001. Median anti-spike titre was lower in anti-CD20 antibodies and fingolimod-treated pwMS compared to those receiving other DMTs, and it correlated with anti-CD20 treatment duration (R − 0.93, p < 0.0001) and with age at vaccination in pwMS not receiving depletive treatments (R − 0.25, p = 0.028). Baseline CD19+ cell count (where available) was higher in the responder group than in non-responders, p < 0.0001. Two symptomatic COVID-19 infections were diagnosed over a median follow-up of 5 months (range 2–7); adverse events were aligned with the published literature. CONCLUSION: Antibody response to anti-COVID-19 vaccines was detected in most of the pwMS analysed, but frequency of responders was reduced in those receiving CD20 depleting therapies compared to other DMTs-treated pwMS. Investigations on cell-mediated immune response are needed to assess whether a protective immune response is elicited also in non-antibody responders. |
format | Online Article Text |
id | pubmed-8891428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-88914282022-03-04 Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis Mariottini, Alice Bertozzi, Andrea Marchi, Leonardo Di Cristinzi, Maria Mechi, Claudia Barilaro, Alessandro Massacesi, Luca Repice, Anna Maria J Neurol Original Communication BACKGROUND: Few data are available so far on the antibody-mediated immune response to anti-SARS-Cov2 vaccination in people with multiple sclerosis (pwMS) treated with disease-modifying treatments (DMTs), therefore this issue was explored in a real-life cohort of pwMS. MATERIALS AND METHODS: Retrospective monocentric study on anti-spike protein antibody response in pwMS who had received vaccination for Sars-Cov2. Adverse events following vaccination were also recorded. RESULTS: One hundred and twenty pwMS were included: 83 females (69%); median age at vaccination 42 years (range 21–73); 112/120 patients (93%) were receiving DMTs at vaccination. Anti-spike protein IgG antibodies were detectable in 102/120 (85%) cases overall, being the proportion lower in pwMS receiving anti-CD20 antibodies (14/31, 45%) compared to non-depletive treatments (77/78, 99%), p < 0.0001. Median anti-spike titre was lower in anti-CD20 antibodies and fingolimod-treated pwMS compared to those receiving other DMTs, and it correlated with anti-CD20 treatment duration (R − 0.93, p < 0.0001) and with age at vaccination in pwMS not receiving depletive treatments (R − 0.25, p = 0.028). Baseline CD19+ cell count (where available) was higher in the responder group than in non-responders, p < 0.0001. Two symptomatic COVID-19 infections were diagnosed over a median follow-up of 5 months (range 2–7); adverse events were aligned with the published literature. CONCLUSION: Antibody response to anti-COVID-19 vaccines was detected in most of the pwMS analysed, but frequency of responders was reduced in those receiving CD20 depleting therapies compared to other DMTs-treated pwMS. Investigations on cell-mediated immune response are needed to assess whether a protective immune response is elicited also in non-antibody responders. Springer Berlin Heidelberg 2022-03-03 2022 /pmc/articles/PMC8891428/ /pubmed/35239006 http://dx.doi.org/10.1007/s00415-022-11003-3 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Communication Mariottini, Alice Bertozzi, Andrea Marchi, Leonardo Di Cristinzi, Maria Mechi, Claudia Barilaro, Alessandro Massacesi, Luca Repice, Anna Maria Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis |
title | Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis |
title_full | Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis |
title_fullStr | Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis |
title_full_unstemmed | Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis |
title_short | Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis |
title_sort | effect of disease-modifying treatments on antibody-mediated response to anti-covid19 vaccination in people with multiple sclerosis |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891428/ https://www.ncbi.nlm.nih.gov/pubmed/35239006 http://dx.doi.org/10.1007/s00415-022-11003-3 |
work_keys_str_mv | AT mariottinialice effectofdiseasemodifyingtreatmentsonantibodymediatedresponsetoanticovid19vaccinationinpeoplewithmultiplesclerosis AT bertozziandrea effectofdiseasemodifyingtreatmentsonantibodymediatedresponsetoanticovid19vaccinationinpeoplewithmultiplesclerosis AT marchileonardo effectofdiseasemodifyingtreatmentsonantibodymediatedresponsetoanticovid19vaccinationinpeoplewithmultiplesclerosis AT dicristinzimaria effectofdiseasemodifyingtreatmentsonantibodymediatedresponsetoanticovid19vaccinationinpeoplewithmultiplesclerosis AT mechiclaudia effectofdiseasemodifyingtreatmentsonantibodymediatedresponsetoanticovid19vaccinationinpeoplewithmultiplesclerosis AT barilaroalessandro effectofdiseasemodifyingtreatmentsonantibodymediatedresponsetoanticovid19vaccinationinpeoplewithmultiplesclerosis AT massacesiluca effectofdiseasemodifyingtreatmentsonantibodymediatedresponsetoanticovid19vaccinationinpeoplewithmultiplesclerosis AT repiceannamaria effectofdiseasemodifyingtreatmentsonantibodymediatedresponsetoanticovid19vaccinationinpeoplewithmultiplesclerosis |